Drug
Elenestinib
Elenestinib: highest development phase Phase 2/3, developed by Blueprint Medicines. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Blueprint Medicines
Trials
| Drug | Phase | Indication |
|---|---|---|
| Elenestinib NCT04910685 | Phase 2/3 | Indolent Systemic Mastocytosis |
| Elenestinib NCT07388511 | Phase 1 |
Latest
No recent events.
Follow Elenestinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.